Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258–62. https://doi.org/10.1038/jhh.2016.71.

Article  CAS  PubMed  Google Scholar 

Del Pinto R, Grassi G, Muiesan ML, Borghi C, Carugo S, Cicero AFG, et al. World hypertension day 2021 in Italy: results of a nationwide survey. High Blood Press Cardiovasc Prev. 2022;29(4):353–9. https://doi.org/10.1007/s40292-022-00519-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Pinto R, Agabiti Rosei C, Borghi C, Cipollini F, Cottone S, De Giorgi GA, et al. May measure month 2022 in Italy: a focus on fixed-dose combination, therapeutic adherence, and medical inertia in a nationwide survey. High Blood Press Cardiovasc Prev. 2024;31(3):309–20. https://doi.org/10.1007/s40292-024-00642-4.

Article  PubMed  PubMed Central  Google Scholar 

Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846–53. https://doi.org/10.1161/hypertensionaha.118.11308.

Article  CAS  PubMed  Google Scholar 

Savaré L, Rea F, Corrao G, Mancia G. Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database. J Hypertens. 2022;40(9):1768–75. https://doi.org/10.1097/hjh.0000000000003215.

Article  PubMed  PubMed Central  Google Scholar 

Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443–62. https://doi.org/10.2165/00003495-200262030-00003.

Article  CAS  PubMed  Google Scholar 

Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869–. https://doi.org/10.1111/j.1751-7176.2010.00360.x. 78.

Article  PubMed  PubMed Central  Google Scholar 

Simonyi G, Burnier M, Narkiewicz K, Rokszin G, Abonyi-Tóth Z, Kovács G, et al. Effect of single-pill versus free equivalent combinations on persistence and major adverse cardiovascular events in hypertension: a real-world analysis. J Hypertens. 2025;43(3):405–12. https://doi.org/10.1097/hjh.0000000000003916.

Article  CAS  PubMed  Google Scholar 

Simonyi G, Ferenci T, Alföldi S, Farsang C. Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. J Int Med Res. 2016;44(5):1087–91. https://doi.org/10.1177/0300060516645004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coca A, Borghi C, Stergiou GS, Ly NF, Lee C, Tricotel A, et al. Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure Lowering therapy. J Hypertens. 2025;43(6):993–1002. https://doi.org/10.1097/HJH.0000000000004002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339.

Article  PubMed  Google Scholar 

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874–2071. https://doi.org/10.1097/hjh.0000000000003480.

Article  CAS  PubMed  Google Scholar 

Rosas-Peralta M, Mancia G, Camafort M, Galván-Oseguera H, Ferrario CM, Alcocer L et al. Single pill combination therapy for hypertension: new evidence and new challenges: combination therapy for hypertension. Trends Cardiovasc Med. 2025. https://doi.org/10.1016/j.tcm.2025.06.004

Article  PubMed  Google Scholar 

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178.

Article  PubMed  Google Scholar 

Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation andmanagement of high blood pressure in adults: a Report of theAmerican College of Cardiology/American Heart Association JointCommittee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114–e218. https://doi.org/10.1161/HYP.0000000000000249

Coca A, Whelton SP, Camafort M, López-López JP, Yang E. Single-pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit? Eur J Intern Med. 2024;126:16–25. https://doi.org/10.1016/j.ejim.2024.04.011.

Article  CAS  PubMed  Google Scholar 

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300. https://doi.org/10.1016/j.amjmed.2008.09.038.

Article  PubMed  Google Scholar 

Chauhan M, Patel JB, Ahmad F. Ramipril StatPearls. Treasure Island: StatPearls Publishing LLC; 2025.

Bulsara KG, Patel P, Cassagnol M, Amlodipine: StatPearls. Treasure Island: StatPearls Publishing LLC; 2025.

Herman LL, Weber P, Bashir K, Hydrochlorothiazide. StatPearls. Treasure Island: StatPearls Publishing LLC; 2025.

Carlos-Escalante JA, de Jesús-Sánchez M, Rivas-Castro A, Pichardo-Rojas PS, Arce C, Wegman-Ostrosky T. The use of antihypertensive drugs as coadjuvant therapy in cancer. Front Oncol. 2021;11:660943. https://doi.org/10.3389/fonc.2021.660943.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sica D. Calcium channel blocker-related periperal edema: Can it be resolved? J clin hypertens (Greenwich). 2003 5(4):291. https://doi.org/10.1111/j.1524-6175.2003.02402.x

Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Salvetti A. Effects of amlodipine, Nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebo-controlled, double-masked, crossover study. Curr Therapeutic Res. 1999.https://doi.org/10.1016/S0011-393X(00)88520-3.

Article  CAS  Google Scholar 

Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and arbs: managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601–7. https://doi.org/10.3949/ccjm.86a.18024.

Article  PubMed  Google Scholar 

Ferri N, Corsini A. Farmacologia clinica Delle Terapie Di associazione Nella prevenzione e nel Trattamento Delle malattie cardiovascolari. G Ital Cardiol. 2025;26(1):6–16. https://doi.org/10.1714/4425.44225.

Article  Google Scholar 

Anderson VR, Perry CM, Robinson DM. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs. 2006;6(6):417–32. https://doi.org/10.2165/00129784-200606060-00012.

Article  CAS  PubMed  Google Scholar 

Keating GM. Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs. 2009;69(9):1239–65. https://doi.org/10.2165/00003495-200969090-00008.

Article  CAS  PubMed  Google Scholar 

Curran MP. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs. 2010;70(2):191–213. https://doi.org/10.2165/11204420-000000000-00000.

Article  CAS  PubMed  Google Scholar 

AIRE Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction Ramipril efficacy (AIRE) study investigators. Lancet. 1993;342(8875):821–8.https://doi.org/10.1016/0140-6736(93)92693-N.

Google Scholar 

GISEN Group. Randomised placebo-controlled trial of effect of Ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano Di studi epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857–63.https://doi.org/10.1016/S0140-6736(96)11445-8.

Article  Google Scholar 

HOPE Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet. 2000;355(9200):253–9.https://doi.org/10.1016/S0140-6736(99)12323-7.

Article  Google Scholar 

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53. https://doi.org/10.1056/nejm200001203420301.

Article  CAS  PubMed